Technology Bundle ID: TAB-892

Method for the Treatment of Multiple Sclerosis

Request More Info
Licensing Contact:
Roland Martin (NINDS)
Therapeutic Area: 
Institute or Center: 

The invention relates to the discovery that humanized antibodies to the interleukin-2 receptor (IL-2R) such as (daclizumab) are effective in treating multiple sclerosis (MS). In particular, it has been discovered that patients who have failed to respond to therapy with interferon-beta show dramatic improvement when treated with daclizumab, with patients showing both a reduction in the total number of lesions and cessation of appearance of new lesions during the treatment period. Daclizumab is effective both in combination with interferon-beta and alone.


EIR Application
PCT Application PCT/US02/38290
Filed on 2002-11-27
PCT Application PCT/US2003/020428
Filed on 2003-06-27
US Application 13/475,688
Filed on 2012-05-18
US Application 13/725,119
Filed on 2012-12-21
US Application 14/139,424
Filed on 2013-12-23
US Application 14/487,012
Filed on 2014-09-15
US Application 14/792,432
Filed on 2015-07-06
US Application 15/234,575
Filed on 2016-08-11
US Application 15/956,458
Filed on 2018-04-18
US Application 16/132,852
Filed on 2018-09-17
US Application 60/393,021
Filed on 2002-06-28
US Pat 7,258,859

Issued 2007-08-21
US Pat 7,575,742

Issued 2009-08-18
US Pat 8,298,525

Issued 2012-10-30
US Pat 8,454,965

Issued 2013-06-04
US Pat 8,636,997

Issued 2014-01-28


Aug 1, 2003

Data Source: